Commission Directive 2004/33/EC of 22 March 2004 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components (Text with EEA relevance)

Article 1	Definitions
Article 2	Provision of information to prospective donors
Article 3	Information required from donors
Article 4	Eligibility of donors
Article 5	Storage, transport and distribution conditions for blood and blood
	components
Article 6	Quality and safety requirements for blood and blood components
Article 7	Autologous donations
Article 8	Validation
Article 9	Transposition
Article 10	Entry into force
Article 11	Addressees

# ANNEX I

# DEFINITIONS

- 1. 'Autologous donation' means blood and blood components collected from an...
- 2. 'Allogeneic donation' means blood and blood components collected from an...
- 3. 'Validation' means the establishment of documented and objective evidence that...
- 4. 'Whole blood' means a single blood donation.
- 5. 'Cryopreservation' means prolongation of the storage life of blood components...
- 6. 'Plasma' means the liquid portion of the blood in which...
- 7. 'Cryoprecipitate' means a plasma component prepared from plasma, fresh-frozen, by...
- 8. 'Washed' means a process of removing plasma or storage medium...
- 9. 'Red cells' means the red cells from a single whole...
- 10. 'Red cells, buffy coat removed' means the red cells from...
- 11. 'Red cells, leucocyte-depleted' means the red cells from a single...
- 12. 'Red cells in additive solution' means the red cells from...
- 13. 'Additive solution' means a solution specifically formulated to maintain beneficial...

- 14. 'Red cells, buffy coat removed, in additive solution' means the...
- 15. 'Buffy coat' means a blood component prepared by centrifugation of...
- 16. 'Red cells, leucocyte-depleted, in additive solution' means the red cells...
- 17. 'Red cells, apheresis' means the red cells from an apheresis...
- 18. 'Apheresis' means a method of obtaining one or more blood...
- 19. 'Platelets, apheresis' means a concentrated suspension of blood platelets obtained...
- 20. 'Platelets, apheresis, leucocyte-depleted' means a concentrated suspension of blood platelets,...
- 21. 'Platelets, recovered, pooled' means a concentrated suspension of blood platelets,...
- 22. 'Platelets, recovered, pooled, leucocyte-depleted' means a concentrated suspension of blood...
- 23. 'Platelets, recovered, single unit' means a concentrated suspension of blood...
- 24. 'Platelets, recovered, single unit, leucocyte-depleted' means a concentrated suspension of...
- 25. 'Plasma, fresh-frozen' means the supernatant plasma separated from a whole...
- 26. 'Plasma, cryoprecipitate-depleted for transfusion' means a plasma component prepared from...
- 27. 'Granulocytes, apheresis' means a concentrated suspension of granulocytes obtained by...
- 28. 'Statistical process control' means a method of quality control of...

#### ANNEX II

## INFORMATION REQUIREMENTS

#### PART A

Information to be provided to prospective donors of blood or blood components

- 1. Accurate educational materials, which are understandable for members of the...
- 2. For both allogeneic and autologous donations, the reasons for requiring...
- 3. Information on the protection of personal data: no unauthorised disclosure...
- 4. The reasons why individuals are not to make donations which...
- 5. Specific information on the nature of the procedures involved either...

IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

- 6. Information on the option for donors to change their mind...
- 7. The reasons why it is important that donors inform the...
- 8. Information on the responsibility of the blood establishment to inform...
- 9. Information why unused autologous blood and blood components will be...
- 10. Information that test results detecting markers for viruses, such as...
- 11. Information on the opportunity for donors to ask questions at...

#### PART B

Information to be obtained from donors by blood establishments at every donation

- 1. Identification of the donor
- 2. Health and medical history of the donor
- 3. Signature of the donor

#### ANNEX III

# ELIGIBILITY CRITERIA FOR DONORS OF WHOLE BLOOD AND BLOOD COMPONENTS

- 1. ACCEPTANCE CRITERIA FOR DONORS OF WHOLE BLOOD AND BLOOD COMPONENTS...
  - 1.1. Age and body weight of donors
  - 1.2. Haemoglobin levels in donor's blood
  - 1.3. Protein levels in donor's blood
  - 1.4. Platelet levels in donor's blood
- 2. DEFERRAL CRITERIA FOR DONORS OF WHOLE BLOOD AND BLOOD COMPONENTS...
  - 2.1. Permanent deferral criteria for donors of allogeneic donations
  - 2.2. Temporary deferral criteria for donors of allogeneic donations
    - 2.2.1. Infections

#### Duration of deferral period

- 2.2.2. Exposure to risk of acquiring a transfusion-transmissible infection
- 2.2.3. Vaccination
- 2.2.4. Other temporary deferrals
- 2.3. Deferral for particular epidemiological situations
- 2.4. Deferral criteria for donors of autologous donations

#### ANNEX IV

#### STORAGE, TRANSPORT AND DISTRIBUTION CONDITIONS FOR BLOOD AND BLOOD COMPONENTS

- 1. STORAGE
  - 1.1. Liquid storage

1.2. Cryopreservation

### 2. TRANSPORT AND DISTRIBUTION

#### 3. ADDITIONAL REQUIREMENTS FOR AUTOLOGOUS DONATIONS

- 3.1. Autologous blood and blood components must be clearly identified as...
- 3.2. Autologous blood and blood components must be labelled as required...

#### ANNEX V

#### QUALITY AND SAFETY REQUIREMENTS FOR BLOOD AND BLOOD COMPONENTS

- 1. THE BLOOD COMPONENTS
- 2. QUALITY CONTROL REQUIREMENTS FOR BLOOD AND BLOOD COMPONENTS
  - 2.1. Blood and blood components must comply with the following technical...
  - 2.2. Appropriate bacteriological control of the collection and manufacturing process must...
  - 2.3. Member States must take all necessary measures to ensure that...
  - 2.4. For autologous donations, the measures marked with an asterisk (\*)...

- (**1**) OJ L 33, 8.2.2003, p. 30.
- (**2**) OJ L 203, 21.7.1998, p. 14.